"4.5.1\tL\u00E9kov\u00E9 interakce\nAminoglutethimid pod\u00E1van\u00FD sou\u010Dasn\u011B s p\u0159\u00EDpravkem DEPO-PROVERA m\u016F\u017Ee v\u00FDrazn\u011B sn\u00ED\u017Eit jej\u00ED biologickou dostupnost. \u017Deny u\u017E\u00EDvaj\u00EDc\u00ED p\u0159\u00EDpravek z d\u016Fvodu antikoncepce by m\u011Bly b\u00FDt sezn\u00E1meny s mo\u017Enost\u00ED jej\u00ED sn\u00ED\u017Een\u00E9 \u00FA\u010Dinnosti p\u0159i sou\u010Dasn\u00E9m u\u017E\u00EDv\u00E1n\u00ED aminoglutethimidu nebo jak\u00E9hokoliv podobn\u00E9ho l\u00E9\u010Diva.\n4.5.2\tJin\u00E9 formy interakc\u00ED\nU\u017E\u00EDv\u00E1n\u00EDm p\u0159\u00EDpravku DEPO-PROVERA mohou b\u00FDt ovlivn\u011Bna n\u00E1sleduj\u00EDc\u00ED laboratorn\u00ED vy\u0161et\u0159en\u00ED:\nhladina gonadotropin\u016F;\nhladina progesteronu v\u00A0plazm\u011B;\nhladina pregnandiolu v\u00A0mo\u010Di;\nhladina testosteronu v\u00A0plazm\u011B (u mu\u017E\u016F);\nhladina estrogen\u016F v\u00A0plazm\u011B (u \u017Een);\nhladina kortizolu v\u00A0plazm\u011B;\ngluk\u00F3zov\u00FD toleran\u010Dn\u00ED test;\nmetopironov\u00FD test.\nN\u011Bkte\u0159\u00ED pacienti u\u017E\u00EDvaj\u00EDc\u00ED MPA mohou m\u00EDt potla\u010Denou funkci nadledvin. MPA m\u016F\u017Ee sn\u00ED\u017Eit hladinu ACTH a hydrokortizonu v\u00A0krvi.\nJe vhodn\u00E9 informovat o\u0161et\u0159uj\u00EDc\u00EDho l\u00E9ka\u0159e/laborato\u0159, \u017Ee krom\u011B endokrinn\u00EDch biomarker\u016F, m\u016F\u017Ee pou\u017Eit\u00ED MPA v\u00A0onkologii tak\u00E9 zp\u016Fsobit \u010D\u00E1ste\u010Dnou adren\u00E1ln\u00ED insuficienci (pokles odpov\u011Bdi hypofyzoadren\u00E1ln\u00ED osy) b\u011Bhem metyrapon-testu. Tud\u00ED\u017E schopnost adren\u00E1ln\u00ED k\u016Fry reagovat na ACTH by m\u011Bla b\u00FDt jasn\u011B demonstrov\u00E1na p\u0159edt\u00EDm, ne\u017E je pod\u00E1n metyrapon.\n"@cs . "4.5\tInterakce s\u00A0jin\u00FDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky a jin\u00E9 formy interakce"@cs . . . "004.005" . . . . .